Tenaris S.A. (TNRSF)
| Market Cap | 30.22B +44.3% |
| Revenue (ttm) | 12.16B +2.8% |
| Net Income | 1.98B -1.2% |
| EPS | 1.92 +4.4% |
| Shares Out | n/a |
| PE Ratio | 15.15 |
| Forward PE | n/a |
| Dividend | 1.19 (4.08%) |
| Ex-Dividend Date | Nov 23, 2026 |
| Volume | 100 |
| Open | 29.15 |
| Previous Close | 29.15 |
| Day's Range | 29.15 - 29.15 |
| 52-Week Range | 18.80 - 30.53 |
| Beta | 0.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Tenaris
Tenaris S.A., together with its subsidiaries, manufactures and supplies steel pipe products and related services for the energy industry and other industrial applications in North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. It provides steel casings to sustain the walls of oil and gas wells during and after drilling; steel tubing for conducting crude oil and natural gas to the surface after drilling has been completed; steel line pipes to transport crude oil and natural gas from wells to refineries, storage... [Read more]
Financial Performance
In 2025, Tenaris's revenue was $11.98 billion, a decrease of -4.33% compared to the previous year's $12.52 billion. Earnings were $1.93 billion, a decrease of -5.09%.
Financial StatementsNews
Tenaris price target raised to $65 from $62 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Tenaris (TS) to $65 from $62 and keeps an Equal Weight rating on the shares.
Tenaris price target raised to $67 from $60 at Piper Sandler
Piper Sandler raised the firm’s price target on Tenaris (TS) to $67 from $60 and keeps a Neutral rating on the shares. The firm notes the company delivered a strong…
What Tenaris (TS) Said on Its Q3 Earnings Call
Tenaris NYSE: TS expects fourth-quarter revenue to rise by close to 10% sequentially and its EBITDA margin to reach around 25%, as higher volumes build on a third quarter that exceeded management's ex...
Tenaris price target raised to $88 from $80 at Barclays
Barclays raised the firm’s price target on Tenaris (TS) to $88 from $80 and keeps an Overweight rating on the shares. The company’s stronger volumes and improved pricing led to…
Tenaris upgraded to Buy from Hold at Kepler Cheuvreux
Kepler Cheuvreux analyst Kevin Roger upgraded Tenaris (TS) to Buy from Hold with a EUR 32 price target
Tenaris (TS) Q3 2026 Earnings Call Transcript
Management flags tariff costs of $140M to $150M per quarter ahead for 2027 pricing.
Tenaris Earnings Call Transcript: Q3 2026
Q3 sales and EBITDA increased, with a 24% EBITDA margin and $3.8B net cash. Q4 revenue is expected to rise close to 10% with margins around 25%, while Middle East recovery remains partial and 2027 growth is supported by offshore and regional demand.
Tenaris Earnings release: Q3 2026
Tenaris released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Tenaris Quarterly report: Q3 2026
Tenaris has published its Q3 2026 quarterly earnings report on November 5, 2026.
Tenaris (TS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Tenaris (TS) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare...
Tenaris reports Q3 EPS $1.01, consensus 83c
Reports Q3 revenue $3.1B, consensus $2.99B.
Tenaris Announces 2026 Third Quarter Results
The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance...
Tenaris price target raised to $62 from $60 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Tenaris (TS) to $62 from $60 and keeps an Equal Weight rating on the shares. Energy services lagged in Q3, notes the…
Made in Ontario, Built for the West: Tenaris Now Producing New Steel Grade in Canada
Proprietary Steel Grade Designed for Challenging Canadian Energy Applications SAULT STE. MARIE, Ontario, Oct. 13, 2026 (GLOBE NEWSWIRE) — Tenaris is now domestically producing its TN 95EY proprietary ...
Tenaris price target raised to $71 from $66 at BofA
BofA raised the firm’s price target on Tenaris (TS) to $71 from $66 and keeps a Buy rating on the shares. On account of rising U.S. pricing and offshore volumes,…
Tenaris price target lowered to $60 from $65 at Morgan Stanley
Morgan Stanley analyst Joe Laetsch lowered the firm’s price target on Tenaris (TS) to $60 from $65 and keeps an Equal Weight rating on the shares.
Tenaris price target lowered to $80 from $82 at Barclays
Barclays analyst J. David Anderson lowered the firm’s price target on Tenaris (TS) to $80 from $82 and keeps an Overweight rating on the shares. With Middle East disruptions continuing,…
Tenaris Q2 Earnings Call Highlights
Tenaris NYSE: TS reported second-quarter sales of $3 billion, down 4% from both a year earlier and the prior quarter, as shipping disruptions in the Middle East delayed deliveries to customers in Iraq...
Tenaris price target raised to $68 from $67 at TD Cowen
TD Cowen raised the firm’s price target on Tenaris (TS) to $68 from $67 and keeps a Buy rating on the shares. The firm updated its model following Q2 results.
Tenaris Earnings Call Transcript: Q2 2026
Second quarter sales and earnings declined due to Middle East disruptions and higher costs, but investments in the Americas and a strong offshore backlog support a positive outlook for Q4. The board doubled the interim dividend, reflecting strong cash generation and balance sheet.
Tenaris Earnings release: Q2 2026
Tenaris released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Tenaris Quarterly report: Q2 2026
Tenaris has published its Q2 2026 quarterly earnings report on August 6, 2026.
Tenaris reports Q2 EPS 95c, consensus 82c
Reports Q2 revenue $2.97B, consensus $2.94B. The company stated, “In the second half, we expect our sales and EBITDA to remain in line with the first half, despite sales continuing…
Tenaris Announces 2026 Second Quarter Results
The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance...
NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
Toronto, Ontario – TheNewswire - July 15, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd...